CDK9 as an Appealing Target for Therapeutic Interventions

Author(s): Shirin Eyvazi, Mohammad Saeid Hejazi, Homan Kahroba, Mozghan Abasi, Reza Eghdam Zamiri , Vahideh Tarhriz*.

Journal Name: Current Drug Targets

Volume 20 , Issue 4 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Cyclin Dependent Kinase 9 (CDK9) as a serine/threonine kinase belongs to a great number of CDKs. CDK9 is the main core of PTEF-b complex and phosphorylates RNA polymerase (RNAP) II besides other transcription factors which regulate gene transcription elongation in numerous physiological processes. Multi-functional nature of CDK9 in diverse cellular pathways proposes that it is as an appealing target. In this review, we summarized the recent findings on the molecular interaction of CDK9 with critical participant molecules to modulate their activity in various diseases. Furthermore, the presented review provides a rationale supporting the use of CDK9 as a therapeutic target in clinical developments for crucial diseases; particularly cancers will be reviewed.

Keywords: CDK9, cardiac pathway, cancer, viral agents, fibrosis, inflammation, RNAP.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 20
ISSUE: 4
Year: 2019
Page: [453 - 464]
Pages: 12
DOI: 10.2174/1389450119666181026152221
Price: $58

Article Metrics

PDF: 15